1Translational Neuropsychiatry Unit,Department of Clinical Medicine,Aarhus University,Risskov,Denmark.
3The Lundbeck Foundation Research Center,MIND,Aarhus University,Aarhus,Denmark.
Acta Neuropsychiatr. 2018 Apr;30(2):111-116. doi: 10.1017/neu.2017.13. Epub 2017 May 8.
The identification of biomarkers for depression is of great clinical relevance as the diagnosis is currently subjective. Recent research points towards sortilin as a potential biomarker for depression, and the aim of the current study was to investigate the serum sortilin level in response to antidepressant treatment.
The study included 56 depressed individuals of which 41 responded to treatment. Depression scores and serum levels of sortilin were measured at baseline and after 12 weeks of antidepressant treatment. Statistical analyses were performed using Stata 13.
The depression score and response to treatment were not predicted by the sortilin level. Likewise, we observed no significant change in serum sortilin levels following 12 weeks of antidepressant treatment. Furthermore, no association between the serum sortilin level and depression score was observed.
The results do not point towards sortilin as a state-dependent biomarker.
抑郁症生物标志物的鉴定具有重要的临床意义，因为目前的诊断是主观的。最近的研究表明分选连接蛋白（sortilin）是抑郁症的一个潜在生物标志物，本研究旨在探讨抗抑郁治疗对血清分选连接蛋白水平的影响。
该研究纳入了 56 名抑郁症患者，其中 41 名对治疗有反应。在基线和抗抑郁治疗 12 周后测量抑郁评分和血清分选连接蛋白水平。使用 Stata 13 进行统计分析。
血清分选连接蛋白水平不能预测抑郁评分和治疗反应。同样，我们也没有观察到抗抑郁治疗 12 周后血清分选连接蛋白水平有显著变化。此外，血清分选连接蛋白水平与抑郁评分之间也没有关联。
结果表明分选连接蛋白不是一种与状态相关的生物标志物。
